BOSTON, February 28, 2014—Rhythm announced today that Keith Gottesdiener, MD, CEO, will present a corporate update at the Cowen and Company 34th Annual Health Care Conference on Monday, March 3, 2014 at 3:00 p.m. EST at the Boston Marriott Copley Place.
About Rhythm
Rhythm is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm is developing the ghrelin peptide agonist, RM-131, for the treatment of diabetic gastroparesis and other GI functional disorders; and the MC4R peptide agonist, RM-493, for obesity and diabetes. Rhythm investors include MPM Capital, New Enterprise Associates, Third Rock Ventures, Ipsen, and Pfizer Ventures. The company is based in Boston, Massachusetts.
